Effect of Exenatide, Sitagliptin, or Glimepiride on β-Cell Secretory Capacity in Early Type 2 Diabetes

Lignende værker

• Different β-cell secretory phenotype in non-obese compared to obese early type 2 diabetes
  af: Gudipaty, Lalitha, et al.
  Udgivet: (2020)
• Reduced β-Cell Secretory Capacity in Pancreatic-Insufficient, but Not Pancreatic-Sufficient, Cystic Fibrosis Despite Normal Glucose Tolerance
  af: Sheikh, Saba, et al.
  Udgivet: (2017)
• Loss-of-Function Mutations in ABCA1 and Enhanced β-Cell Secretory Capacity in Young Adults
  af: Rickels, Michael R., et al.
  Udgivet: (2015)
• β-Cell Secretory Capacity and Demand in Recipients of Islet, Pancreas, and Kidney Transplants
  af: Rickels, Michael R., et al.
  Udgivet: (2010)
• Comparison of the efficacy of sitagliptin and glimepiride dose‐up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination
  af: Shimoda, Seiya, et al.
  Udgivet: (2013)